Event Participants
Executives
2
Balakrishnan Natesan Kaushik, Prabhat Agrawal
Analysts
17
Akhil Parekh, Akshat Mehta, Alok Dalal, Arnav Sakhuja, Bharat Shah, Chintan Sheth, Deepak Ajmera, Karan Gupta, Khushi, Kumar Saurabh, Nikhil, Nitin Agarwal, Pinoy Jeriwala, Rahul Dani, Rashmi Gohill, Sidharth Negandhi, Simran Thakkar, Vansh Solanki
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Consolidated Revenue | ₹1,940 crores | +38.2% YoY; like-for-like growth (ex-net margin recognition base and divested subsidiary) +40% YoY; low-margin business exits impacted reported growth by ~2.5% |
| Organic Revenue Growth | 17.8% reported / 19.6% LFL | Exceeds IPM growth of 13.8%; adjusted for deliberate exits, organic growth was ~22% |
| Inorganic Revenue Growth | 20.4% | Entirely from calendarization of FY26 acquisitions; no new acquisitions in Q1 |
| Gross Margin | 11.4% | +147 bps YoY; driven by scale-led procurement efficiencies, MedTech mix (~higher-margin demand-generation role), and exit from low-margin accounts |
| EBITDA | ~₹97 crores | +94% YoY; margin of 5%, +143 bps YoY |
| PAT (Base) | ₹52 crores | +72% YoY; PAT margin 2.7% |
| PAT (Attributable to Owners) | ₹38 crores | +37% YoY; minority interest ₹14 crores (~27% of pre-MI profit) |
| Net Working Capital Days | 61 days | Improved from 66 days a year ago; continued structural efficiency gains |
| ROCE | 21.1% | Nearly doubled from 11.5% YoY; ahead of full-year FY26 |
| ROE | 20.4% | Up from 9% YoY; ahead of full-year FY26 |
| Interest Cost | ~₹200 crores debt | Increase QoQ due to full-quarter impact of acquisition debt taken late Q4 FY26; expected broadly stable |
| Tax Rate (guidance) | 22.5% | Q1 includes deferred tax asset benefit; FY28-29 guidance to be revisited close of FY27 |
Geographic & Segment Commentary
MedTech: Revenue on track to cross ₹1,000 crores in FY27 on an organic basis. Gross and EBITDA margins in MedTech are structurally higher than core pharma distribution due to a demand-generation (full commercial) role rather than pure fulfillment. Focus is on deepening existing manufacturer collaborations and building organic capability. Management targets ~20% growth in MedTech over 3–5 years without further acquisitions, given limited competition and higher value-added opportunities.
Pharmaceutical Distribution (Core): Organic growth of ~19.6% LFL against IPM growth of 13.8%. Gross margin improvement driven by scale-led procurement benefits; business is heavily fulfillment-oriented. Deliberate exits of low-margin accounts (primarily subsistence business, not hospitals) continued in Q1, reducing reported growth by ~2.5%. Platform serves 72,000+ retail customers, 2,300+ hospital customers, 83,400+ SKUs, with 138 warehouses across 475 districts in 19 states.
Visan Sai Pharma (Andhra Pradesh): Small acquisition completed to build surgical consumable distribution capability in AP; will be integrated with an existing AP business, providing diversification into higher-margin surgical consumables. Revenue contribution not material to group scale.
Company-Specific & Strategic Commentary
M&A Strategy Shift (Consolidation Phase): Management has deliberately paused large acquisitions for FY27 after two years of significant M&A activity. Priority is integration and organic growth on the existing platform. Opportunities exist (plenty of willing sellers, limited organized buyers) but management views acquisitions as a means, not an end — open to compelling deals, particularly in Q4FY27.
Minority Interest Call Options: All non-wholly-owned acquisitions carry contractually defined call options exercisable over 2–5 years at valuation multiples consistent with original acquisition terms. Minority profit share is reinvested in business, not distributed. Buyouts can be funded via parent- or subsidiary-level capital, with the highest EPS-accretive deployment prioritized.
Cash Flow Utilization: Internal accruals now fund incremental working capital growth. Excess cash (after 50% EBITDA-to-OCF conversion guidance) will be deployed across minority buyouts, debt repayment, or acquisitions — whichever maximizes EPS; no dividends planned.
Two-Way Network Moat: 3,000+ manufacturer relationships and 72,000+ retail customers create a two-way network effect — broad product range/fill rate/tech-enabled service for retailers; pan-India reach and access to 475 districts for principals — which management views as extremely difficult to replicate.
Operational Efficiency: Net working capital days at 61 days (from 66 days YoY); ROCE and ROE nearly doubled YoY to 21.1% and 20.4%, respectively. Depreciation normalized at Q1 level; Q4 had accelerated depreciation on certain machines given their revenue profile.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Consolidated Revenue Growth | ~23% YoY, FY27 (excluding new acquisitions) | Includes 11–12% from calendarization of prior-year acquisitions, rest organic; organic forecast built on lower-than-current IPM growth assumption |
| EBITDA Margin | 5%, FY27 (delivered in Q1) | Management continues to target higher margins sequentially; may revise guidance upward after Q2 if first-half performance supports |
| EBITDA to Operating Cash Flow Conversion | 50%, FY27 | OCF defined after working capital changes; seasonality noted (Q2 typically highest business, requiring inventory build-up) |
| Tax Rate | 22.5%, FY27 | Deferred tax assets exist; FY28-29 rate to be guided closer to FY27 close |
| Interest Cost | Broadly stable range | Full-quarter impact of ₹200 crores acquisition debt already reflected in Q1; not expected to materially rise |
| ROE / ROCE (Medium Term) | ROE 25–30% achievable in 3–4 years | Assumes ~20% organic growth without incremental acquisitions; operating leverage + gross margin expansion |
| Company Growth Rate (Medium Term) | 20%+ annually | Over next 3–4 years, organically + small tuck-in acquisitions; management confirms no large M&A needed to sustain this |
| EBITDA Margin (Medium Term) | Beyond 6% | Internal aspiration higher than 6%, contingent on 20% growth and operating leverage over next 3–4 years |
Risks & Constraints
| Risk | Context |
|---|---|
| IPM Growth Rate Uncertainty | IPM has moved from 7–9% to double-digit (13.8% in Q1), driven by volume growth, but management cannot isolate the underlying cause. Cyclicality (2023: 16% not sustained) raises risk that growth reverts to mean; company's organic forecast is built on conservative (lower) IPM assumptions. |
| Interest Cost Burden | ~₹200 crores acquisition debt carries full-quarter interest from Q1; interest cost expected to stay broadly flat. No explicit deleveraging plan if acquisitions resume. |
| Minority Buyout Obligations | Contractual call options over 2–5 year timelines require capital for buyouts of residual stakes; obligations not all due in FY27, but funding mechanism (parent vs subsidiary) yet to be determined for each — potential drag on cash if not managed strategically. |
| Working Capital Seasonality | Q2 is the peak season for pharma industry (typically 25%+ of annual sales), requiring inventory build-up that affects quarterly OCF. Management guidance is annual (50% OCF conversion), not quarterly — seasonal visibility limited. |
| Generic Drug Mix Shift | Trade generics/generic share in IPM is increasing. Entero participates in patented, branded generic, and trade generic segments (not pure generic), but margin pressure on generic segments could constrain distribution spreads if competition intensifies. |
Q&A Highlights
Growth Outlook & M&A Strategy
- Question: With M&A muted and IPM at 7–9%, what growth can Entero sustain over 3–4 years, and what ROCE is achievable without acquisitions? (Bharat Shah, BCS Capital)
- Answer: Management confirmed 20%+ annual growth target (organically + small acquisitions) over 3–4 years, achievable without meaningful M&A. ROCE target of 25–30% plausible at 20% growth with no incremental acquisition-driven capital deployment. Margin expansion driven by MedTech contribution, procurement scale, and exit of low-margin accounts. (Prabhat Agrawal)
Minority Interest & Cash Flow Mechanics
- Question: How does cash flow return from subsidiaries to the parent, and what does the minority buyout mechanism entail? (Arnav Sakhuja, Ambit Capital)
- Answer: Subsidiaries are funded via intercompany deposits/loans; as they generate profits, loans are repaid to the parent for funding future acquisitions. Minority interests have contractually defined call options (valuation multiples and timelines predefined at acquisition), exercisable within 2–5 years. Buyout funding flexibility exists — parent- or subsidiary-level capital, whichever maximizes EPS accretion. (Prabhat Agrawal)
Margin Trajectory & Q4-to-Q1 Improvement
- Question: What drove the sequential margin improvement from Q4 to Q1, and can further improvement be expected? (Akshat Mehta, Seven Rivers Holding)
- Answer: Q4 had one-off items that suppressed margin; ex-one-offs, the company was already near 5%. Q1 reflects full-year guidance level. Management aims to sustain and build further on margins, with higher sequential targets. Interest cost increase between Q4/Q1 reflects full-quarter impact of ~₹200 crores acquisition debt taken late Q4 FY26; expected broadly stable thereafter. (Prabhat Agrawal, Balakrishnan Kaushik)
Revenue Calendarization & Government Project Timing
- Question: Why did inorganic growth decline from ~26% in Q4 to 20.4% in Q1, a ~₹60–70 crore difference? (Chintan Sheth, Girik Capital)
- Answer: Q4 had a high base from government projects (CMPP contracts related to diagnostics supply) where billing was pulled forward due to government budget year-end closure. Q1 revenue was therefore lower relative to this base — the only material factor. (Prabhat Agrawal)
IPM Growth & Sustainability
- Question: What is driving the improvement in IPM growth, and is the 13.8% level sustainable? (Alok Dalal, Jefferies)
- Answer: IPM improvement is volume-led, positive across therapy areas with no geographical concentration. Management cannot isolate a specific driver and cannot forecast IPM beyond the near term, but Entero's organic plan is built on conservative (lower) IPM assumptions. Despite the conscious 2.5% growth cut from low-margin exits, organic LFL growth was ~22% in Q1. (Prabhat Agrawal)
Working Capital & Debt-Free Growth
- Question: With margin improvement, can internal accruals now fund incremental working capital, and will incremental debt be avoided? (Kumar Saurabh, Scientific Investing)
- Answer: Yes — OCF positive after accounting for working capital changes means internal accruals cover growth needs. Excess cash (beyond the 50% OCF conversion) will be deployed across acquisitions, minority buyouts, or debt repayment — whichever gives the highest incremental EPS; no dividends planned. PBT-to-EBITDA conversion improved from 33% to ~60% over two years and management expects continued improvement. (Prabhat Agrawal)
Depreciation & Tax Normalization
- Question: Depreciation decreased QoQ despite acquisitions — what is the go-forward range, and is a 25% tax rate a fair assumption post-FY28? (Vansh Solanki, RSPN Ventures)
- Answer: The Q4 spike was due to accelerated depreciation on certain machines given their revenue profile. Q1 depreciation level is the going-forward run rate, subject to new major capex. Deferred tax assets exist; FY27 guidance is 22.5% tax rate; FY28-29 guidance will be provided closer to FY27 close. (Balakrishnan Kaushik)
MedTech Growth & Margin Profile
- Question: In integrating MedTech acquisitions, what value-creation opportunities exist versus traditional pharma, and is 20%+ growth possible on the current MedTech platform? (Nitin Agarwal, DAM Capital)
- Answer: MedTech offers superior opportunities for pan-India national-level collaborations, demand-generation (end-to-end) roles, and far fewer distribution competitors. 20%+ growth is the conservative assumption for modeling; upside exists. MedTech revenue comfortably on track to exceed ₹1,000 crores organic in FY27. (Prabhat Agrawal)
EBITDA Margin Sustainability & Opex Components
- Question: Is the 5% EBITDA run rate sustainable, and is other opex clean going forward? (Chintan Sheth, Girik Capital)
- Answer: The ₹11 crores one-off in Q4 did not flow entirely through other expenses — part impacted gross margin. The 5% margin is a sustainable run rate; management sees room for further expansion. (Prabhat Agrawal)
Working Capital Guidance & Q1 Performance
- Question: With working capital days improving to 61 in Q1, will there be revised guidance? (Alok Dalal, Jefferies)
- Answer: No revision based on one quarter. Guidance stays at EBITDA-to-OCF conversion of 50% (annual); management may provide updated second-half guidance after Q2, given pharma seasonality (Q2 is typically the peak business quarter requiring inventory build-up). Working capital numbers disclosed quarterly for transparency. (Prabhat Agrawal)
Key Takeaway
Entero Healthcare delivered a strong Q1 FY27, with consolidated revenue at ₹1,940 crores (+38.2% YoY; +40% LFL) and EBITDA margin hitting 5% (+143 bps YoY) — achieving full-year guidance in the first quarter. Organic growth of 19.6% LFL (or 22% excluding deliberate low-margin exits) outpaced IPM's 13.8%, aided by the two-way network moat across 72,000+ retail and 2,300+ hospital customers, 83,400 SKUs, and 138 warehouses. ROCE and ROE nearly doubled YoY to 21.1% and 20.4%, with working capital days improving to 61. Management has shifted strategy to consolidation and integration — no new acquisitions planned in FY27 — targeting 20%+ organic growth, 5% EBITDA margin (with upside possible after Q2), and 50% EBITDA-to-OCF conversion. Margin expansion is driven by scale-led procurement benefits and MedTech's higher-margin demand-generation mix, with MedTech crossing ₹1,000 crores revenue organically in FY27. Key watch points: IPM growth sustainability (management unable to forecast), interest cost stability (₹200 crores debt), minority buyout obligations over 2–5 years, and the pace of working capital efficiency gains. Management remains confident of maintaining 20%+ growth over 3–4 years without incremental acquisitions, targeting 25–30% ROCE in that timeframe.